Y Intercept Hong Kong Ltd Has $5.11 Million Stock Position in AstraZeneca PLC $AZN

Y Intercept Hong Kong Ltd increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 111.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 66,643 shares of the company’s stock after purchasing an additional 35,148 shares during the period. Y Intercept Hong Kong Ltd’s holdings in AstraZeneca were worth $5,113,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of AZN. NewSquare Capital LLC grew its stake in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after buying an additional 218 shares in the last quarter. Richardson Financial Services Inc. boosted its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after acquiring an additional 149 shares in the last quarter. Rakuten Investment Management Inc. bought a new position in AstraZeneca in the third quarter valued at approximately $31,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after purchasing an additional 275 shares during the last quarter. Finally, VSM Wealth Advisory LLC acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at $33,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 1.4%

Shares of AZN stock opened at $92.95 on Friday. The stock has a 50-day moving average of $91.87 and a 200-day moving average of $83.59. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market cap of $288.31 billion, a price-to-earnings ratio of 30.88, a PEG ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $96.51.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The firm had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same quarter in the previous year, the company earned $2.08 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AZN shares. TD Cowen reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Wall Street Zen cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Jefferies Financial Group began coverage on shares of AstraZeneca in a report on Monday, October 27th. They set a “buy” rating for the company. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday. Finally, Morgan Stanley restated an “overweight” rating and set a $103.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.